Business Description
Prime Medicine Inc
NAICS : 541714
SIC : 2833
ISIN : US74168J1016
Description
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.26 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | -0.2 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -2.33 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -455 | |||||
| 3-Year EPS without NRI Growth Rate | -133.3 | |||||
| 3-Year FCF Growth Rate | -181.3 | |||||
| 3-Year Book Growth Rate | 246 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 12.81 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.31 | |||||
| 9-Day RSI | 39.89 | |||||
| 14-Day RSI | 40.83 | |||||
| 6-1 Month Momentum % | -37.61 | |||||
| 12-1 Month Momentum % | -43.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.5 | |||||
| Quick Ratio | 6.5 | |||||
| Cash Ratio | 4.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.7 | |||||
| Shareholder Yield % | -41.92 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -26598.5 | |||||
| Net Margin % | -27406.13 | |||||
| FCF Margin % | -23789.63 | |||||
| ROE % | -114.56 | |||||
| ROA % | -82 | |||||
| ROIC % | -217.71 | |||||
| ROC (Joel Greenblatt) % | -350.66 | |||||
| ROCE % | -91.88 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 411.25 | |||||
| PB Ratio | 2.28 | |||||
| Price-to-Tangible-Book | 2.27 | |||||
| EV-to-EBIT | -1.4 | |||||
| EV-to-EBITDA | -1.44 | |||||
| EV-to-Revenue | 371.55 | |||||
| EV-to-Forward-Revenue | 664.04 | |||||
| EV-to-FCF | -1.56 | |||||
| Price-to-Net-Current-Asset-Value | 4.22 | |||||
| Price-to-Net-Cash | 13.16 | |||||
| Earnings Yield (Greenblatt) % | -71.43 | |||||
| FCF Yield % | -44.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PRME
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Prime Medicine Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.8 | ||
| EPS (TTM) ($) | -2.06 | ||
| Beta | 0 | ||
| Volatility % | 81.14 | ||
| 14-Day RSI | 40.83 | ||
| 14-Day ATR ($) | 0.280243 | ||
| 20-Day SMA ($) | 3.6425 | ||
| 12-1 Month Momentum % | -43.1 | ||
| 52-Week Range ($) | 2.85 - 9.86 | ||
| Shares Outstanding (Mil) | 131.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Prime Medicine Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Prime Medicine Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Prime Medicine Inc Frequently Asked Questions
What is Prime Medicine Inc(PRME)'s stock price today?
The current price of PRME is $3.29. The 52 week high of PRME is $9.86 and 52 week low is $2.85.
When is next earnings date of Prime Medicine Inc(PRME)?
The next earnings date of Prime Medicine Inc(PRME) is 2025-02-28 Est..
Does Prime Medicine Inc(PRME) pay dividends? If so, how much?
Prime Medicine Inc(PRME) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers